Literature DB >> 6260393

Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.

T H Wasserman, T L Phillips, G Ross, L J Kane.   

Abstract

This paper reports on the ability of the radioprotector WR-2721 to protect bone marrow colony forming units from the cell kill of various cytotoxic chemotherapy agents including nitrogen mustard, cyclophosphamide, BCNU, cis-platinum, and 5-fluorouracil. The dose-modifying factors seen with these compounds ranged from 1.5 to 4.6. Protection by WR-2721 seems to be selective for the bone marrow endpoint, in that similar protection against EMT6/SF tumor cell kill was not seen with the same combination of the cytotoxic chemotherapy agents and WR-2721 as measured by regrowth delay. The implications of these data are discussed in the paper.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6260393

Source DB:  PubMed          Journal:  Cancer Clin Trials        ISSN: 0190-1206


  19 in total

Review 1.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 2.  A risk-benefit assessment of amifostine in cytoprotection.

Authors:  M Mabro; S Faivre; E Raymond
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 3.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Zebrafish as a model system to screen radiation modifiers.

Authors:  Misun Hwang; Cha Yong; Luigi Moretti; Bo Lu
Journal:  Curr Genomics       Date:  2007-09       Impact factor: 2.236

5.  Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

Authors:  J A van Laar; C L van der Wilt; M Treskes; W J van der Vijgh; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.

Authors:  E J Shpall; S M Stemmer; S I Bearman; S Myers; M Purdy; R B Jones
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 7.  Amifostine: potential for clinically useful cytoprotection.

Authors:  G T Budd; V Lorenzi; R Ganapathi; D Adelstein; R Pelley; T Olencki; D McLain; R M Bukowski
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

Review 8.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.

Authors:  M Treskes; U Holwerda; L G Nijtmans; H M Pinedo; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.